Vol 14, No 1 (2018)
Review paper
Published online: 2018-02-28
Immunotherapy of cancer — safety issues
DOI: 10.5603/OCP.2018.0002
Oncol Clin Pract 2018;14(1):40-42.
Abstract
Using of immune checkpoints inhibitors, including mainly anti-PD-1, is a new, effective strategy of therapy of advanced malignancies. In safety profile the main danger are autoimmunological adverse events, and their management includes patient’s education, interdisciplinary cooperation, using diagnostic-therapeutic algorithms and often immediate administration of corticosteroids.
Keywords: anti-PD-1anti-CTLA-4nivolumabpmembrolizumabipilimumabadverseeventsimmunotherapy
References
- Rutkowski P. Złośliwe nowotwory skóry. Wyd. 2. Via Medica .
- Rutkowski P. Nowe terapie w czerniakach. Via Medica .
- Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19): 1845–1855.
- Vanpouille-Box C, Lhuillier C, Bezu L, et al. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology. 2017; 6(11): e1373237.
- Thallinger C, Füreder T, Preusser M, et al. Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr. 2017 [Epub ahead of print].
- Robert C, Ribas A, Wolchok J, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014; 384(9948): 1109–1117.
- Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26): 2521–2532.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320–330.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine. 2015; 373(1): 23–34.
- Wolchok J, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2017; 377(14): 1345–1356.
- Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017; 390(10105): 1853–1862.
- Haanen JB, Carbonnel F, Robert C, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv119–iv142.
- Weber JAS, Topalian SL, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 33, 2015 (suppl; abstr. ; 9018: 2015.
- Escudier B, Motzer RJ, Sharma P, et al. CheckMate 025 investigators, CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
- Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123–135.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.